Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia by Cazorla, Pilar et al.
© 2012 Cazorla et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2012:8 247–257
Neuropsychiatric Disease and Treatment
Safety and tolerability of switching to asenapine 
from other antipsychotic agents: pooled results 
from two randomized multicenter trials in stable 
patients with persistent negative symptoms  
in schizophrenia
Pilar Cazorla1
Mary Mackle2
Jun Zhao2
Xianwei Ha2
Armin Szegedi2
1Formerly, Merck Rahway,  
2Merck, Rahway, NJ, USA
Correspondence: Armin Szegedi 
Merck, 126 E Lincoln Avenue,  
Rahway, NJ, USA 
Tel +1 732 594 5825 
Email armin.szegedi@merck.com
Background: In clinical practice, clinicians often need to switch antipsychotic medications 
in patients with schizophrenia to optimize treatment outcomes. Here, we describe the safety 
and tolerability of switching existing antipsychotic treatments to asenapine or olanzapine 
monotherapy using various switching regimens.
Methods: Data were pooled from 949 patients in two 26-week randomized double-blind studies. 
Patients with persistent negative symptoms of schizophrenia, stable for at least 5 months prior 
to screening and 1 additional month before randomization, were randomized to and treated with 
either asenapine (n = 485) or olanzapine (n = 464), and were tapered off existing antipsychotic(s) 
at variable rates within 28 days.
Results: Prior to randomization, most patients were treated with second-generation antipsy-
chotics (SGAs) (asenapine: 79.6%; olanzapine: 78.2%) and first-generation antipsychotics 
(FGAs) (31.1%; 29.7%), while depot formulations were used by 12.4% and 11.4%,   respectively. 
Median time to taper off previous antipsychotics was 7 days, with approximately 40% of patients 
abruptly discontinuing their previous medication. Similar percentages of patients in each group 
reported at least one adverse event (AE) (asenapine: 76.9%; olanzapine: 75.2%). The majority 
of AEs occurred within the first 28 days. The most frequently reported AEs were somnolence, 
insomnia, and headache. The incidence of AEs in patients switching from SGAs, FGAs, or depot 
medications was similar between asenapine and olanzapine (77.5% vs 74.6%, 75.5% vs 79.7%, 
85.0% vs 86.8%, respectively). AEs were more frequent in subjects previously treated with two 
antipsychotics (asenapine: 79.4%; olanzapine: 83.9%) versus one antipsychotic (asenapine: 
76.3%; olanzapine: 72.2%) in the switch period.
Conclusion: The presented data from post hoc pooled analyses may provide practical guidance 
for physicians switching partially stabilized patients with schizophrenia and persistent negative 
symptoms to asenapine or olanzapine.
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Introduction
A substantial proportion of patients treated with antipsychotics either fail to respond 
adequately or do not tolerate drug treatment well, which may result in treatment 
discontinuation.1–6 Because combining medications may increase the potential for 
adverse drug reactions and may also make adherence problematic, clinicians often 
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seek to switch these patients to an alternative drug, hoping 
for greater efficacy and/or better tolerability. Patients may 
be switched between multiple antipsychotics until an effec-
tive and acceptably tolerated treatment has been identified. 
The decision of whether, when, and how to switch is usually 
made by weighing the potential risks before, during, and 
following the transition from one antipsychotic to another.5,7 
Certain strategies may be more appropriate than others in 
individual cases. In clinical situations, in which a patient has 
discontinued treatment and an exacerbation of symptoms has 
occurred, a change to an alternative medication can often be 
quickly implemented. The situation is more complex, and 
clinicians may be more hesitant to change treatment, if a cer-
tain level of symptom control has already been achieved with 
the existing drug, yet the efficacy is not satisfactory and/or 
tolerability issues make a longer-term treatment   problematic. 
In such situations, the clinician will often have to make a 
decision on the most appropriate switching regimen for a 
given patient. The clinician will seek to answer questions 
such as: how quickly can I safely switch from the previous 
medication to the new medication? Is a cross-tapering period 
required? If “yes,” how long should the cross-tapering period 
be? Does it matter whether I switch a patient from a previous 
first-generation antipsychotic (FGA) or second-generation 
(SGA)? Can I safely switch the patient from a previous 
depot medication?
These questions are of particular clinical importance if a 
new treatment becomes available to the clinician. To inform 
the clinician facing the need for a switch to such a new treat-
ment option, clinical data from studies in which switching 
has been performed are particularly informative, especially 
when they come from substantial numbers of patients.
Asenapine is an antipsychotic with a unique pharma-
cological profile that is approved for adults in the USA for 
the treatment of schizophrenia and the acute treatment – as 
monotherapy or adjunctive therapy to lithium or valproate – 
of manic or mixed episodes of bipolar I disorder. In the EU, 
it is approved for the treatment of moderate to severe manic 
episodes associated with bipolar I disorder. This report was 
written to provide empirical data on switching regimens 
using pooled data from a large sample of patients previously 
stabilized on various treatments and then switched. Two 
large, randomized, double-blind, multicenter clinical trials 
with identical design were retrospectively analyzed for this 
purpose. Both studies included patients with persistent nega-
tive symptoms in schizophrenia, whose positive symptoms 
were stabilized with one or more antipsychotics and who were 
switched to the study medications asenapine or olanzapine 
as monotherapies for 26 weeks following a 4-week period 
during which the previous medication was tapered off. These 
two studies offer a good opportunity for a comprehensive 
post hoc evaluation of the safety and tolerability of switching 
to asenapine, as well as to olanzapine, using different switch 
regimes controlled by the clinician. The aim of this study is to 
provide guidance for physicians who seek to switch partially 
stabilized patients with schizophrenia from their existing 
antipsychotic(s) to either asenapine or olanzapine.
Methods
This analysis incorporates results from two studies with 
identical design (Figure 1). A total of 949 patients received 
at least one dose of double-blind trial medication.
1.	 Study A7501013 (November 2004 to December 2008) 
included 468 patients, randomized and treated to receive 
either asenapine (n = 244) or olanzapine (n = 224).8
2.	 Study P25543 (March 2005 to July 2006) included 
481 patients randomized and treated to receive either 
asenapine (n = 241) or olanzapine (n = 240).9
These studies were randomized, double-blind, multi-
center trials conducted in patients with persistent negative 
symptoms of schizophrenia. The main results of these stud-
ies have been reported previously.10 Psychiatric diagnosis 
was corroborated with the Mini International Neuropsychi-
atric Interview; patients were clinically stable on their posi-
tive symptoms for at least 5 months at the time of screening 
and were subsequently followed by a prospective 30-day 
observation period before baseline. Continued stability 
had to be demonstrated, as subjects continued taking their 
pretrial antipsychotic medication. “Stability” was defined 
as no significant changes in symptoms, no periods of 
  hospitalization/imprisonment, or no increase in the level of 
psychiatric care due to worsening symptoms. This 6-month 
period of stability before baseline provided unambiguous 
data regarding pretrial treatment stability and provided the 
basis for adequate characterization of a patient’s clinical 
progression during the switch period. Clinical evaluations 
included the Negative Symptoms Assessment 16 scale and 
the Positive and Negative Syndrome Scale (PANSS) as 
well as safety and tolerability assessments. Patients were 
randomized 1:1 at baseline to receive either asenapine or 
olanzapine, administered over 26 weeks. The first 4 weeks 
(up to 28 days) constituted a switch period, during which 
the pre-switch antipsychotic medication was discontinued. 
The first dose of asenapine or olanzapine was coadmin-
istered with the existing medication(s). Subjects were 
then tapered off their existing antipsychotic(s) at variable 
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rates and based on the investigator’s clinical judgment. 
The maximum tapering period was scheduled 28 days’ 
post-randomization. This was followed by monotherapy 
with the study drug for the remainder of the study duration. 
Safety, efficacy, and tolerability data were analyzed over 
the duration of the study.
Study drug and other treatments
The packaging and labeling of the clinical trial medica-
tion maintained a double-blind, double-dummy design. 
Fast-  dissolving asenapine tablets and oral film-coated 
  olanzapine tablets were made to appear identical to their 
matched placebo controls. Sublingual asenapine was admin-
istered at 5 mg twice daily (bid) for the first week of therapy 
and then at 5 or 10 mg bid at the discretion of the   investigator. 
Olanzapine was administered at 10 mg once daily (qd) for 
the first week and then 5–20 mg qd at the discretion of the 
investigator.
Subjects could continue to receive concomitant pro-
pranolol or anticholinergics for extrapyramidal syndrome 
(EPS) during the 30-day prospective observation period. 
Following randomization to study treatment, subjects were 
permitted to continue receiving concomitant medication 
for the treatment of EPS for the first week of double-blind 
therapy. After 1 week, an attempt was made to gradually 
decrease concomitant medication for the treatment of EPS, 
with complete discontinuation by day 28 unless a require-
ment for continued treatment was documented. If EPS reap-
peared, the medications were reinstituted and additional EPS 
assessments were performed.
Benzodiazepines (,4 mg/day lorazepam or equiva-
lent dose) could be used for the management of agitation 
or anxiety. Partial benzodiazepine agonists, including 
  zolpidem 2.5–10 mg/day, zaleplon 5–20 mg/day, or zopiclone 
7.5–15 mg/day, could be used on a daily basis for insomnia or 
sleep disturbances. Any equivalent short half-life nonbenzo-
diazepine hypnotic could be substituted if zolpidem, zaleplon, 
or zopiclone were not available. It was recommended that no 
more than half of the recommended maximum suggested 
hypnotic dose be used for patients .65 years of age. These 
drugs were not used 12 hours prior to assessment.
Statistical evaluations
Switching strategy was determined by the investigator 
according to the individual patient, with no specific switch-
ing strategy offered by the protocol. The mean and median 
number of days to finish switching, as well as the inter-
quartile range and its Kaplan–Meier plot, were measured 
for both treatment groups. The distribution difference of the 
time to event between groups was tested by a log-rank test. 
The percentage of patients reporting at least one adverse 
event (AE) was summarized for each treatment group. 
AEs were summarized by the antipsychotic drug class 
with which patients were treated during the switch period 
(FGA, SGA, or depot), by the number of antipsychotics 
used in-treatment, and by the individual antipsychotic drug. 
Sensitivity analyses were also performed; these excluded 
subjects who switched from olanzapine, as olanzapine 
was the active study control and this may have led to 
confounding results.
Randomization
Screening Baseline
Asenapine 5–10 mg bid
Up to 4 weeks
antipsychotic
switch
Olanzapine 5–20 mg qd
26-week treatment 30-day stable
observation
period
5-month history of
stable negative
symptoms prior
to screening
Figure 1 Trial design.
Abbreviations: bid, twice daily; qd, once daily.
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Results
Patient baseline demographics and characteristics were simi-
lar between the asenapine and olanzapine treatment groups 
in both studies (Table 1).
Approximately two-thirds of the patients in this study 
switched to asenapine or olanzapine from previous therapy 
with one antipsychotic and approximately one-quarter from 
two or more (Table 2). SGA antipsychotics comprised the 
majority (almost 80%) of the used pre-switch antipsychotics. 
The percentage of patients previously treated with an FGA 
or SGA was similar between the asenapine and olanzapine 
treatment groups.
There were no major differences between treatment 
groups in the tapering strategies. Over 40% of patients in 
both treatment groups were discontinued abruptly (defined 
as #3 days of switch period). Figure 2 shows a Kaplan–Meier 
curve of time to cessation of antipsychotic therapy during the 
switch period (P = 0.4374, log-rank test). Overall, the timing 
of the switch or duration of the tapering period was similar 
between the two treatment groups. The median (interquartile 
range) was 7.0 (1.0, 20.0) days for asenapine and 7.0 (1.0, 
17.0) days for olanzapine.
In the asenapine group on the day that the switch 
occurred, the mean treatment doses of previous therapies 
were:   olanzapine 14.1 mg/day, risperidone 6.2 mg/day, 
quetiapine 378.5 mg/day, ziprasidone 97.5 mg/day, and 
aripiprazole 18.9 mg/day. For olanzapine, the mean treatment 
doses of previous therapies were: olanzapine 13.2 mg/day, 
risperidone 6.8 mg/day, quetiapine 453.6 mg/day,   ziprasidone 
93.6 mg/day, and aripiprazole 21.0 mg/day.
A slight decrease from baseline was observed on day 28 
for PANSS positive subscale and PANSS Marder-factor 
positive scores (mean change [standard deviation (SD)]) both 
with asenapine (-0.5 [2.34] and -1.1 [2.86], respectively) and 
olanzapine (-0.6 [2.12] and -1.2 [2.70], respectively).
Discontinuations
Overall discontinuation rates were numerically higher in the 
asenapine group (171/467; 36.6%) over the full treatment 
period than with olanzapine (111/452; 24.6%). Difference 
in discontinuation rates was compared for the abrupt-switch 
versus slow-tapering protocols. The discontinuation rate of 
patients in the asenapine group (N = 467) switched abruptly 
was 38.8% (81/209) and 36.5% (62/170) in patients switched 
by slow tapering. The overall discontinuation rate in patients 
switched to olanzapine (n = 452) was 29.7% (58/195) in 
patients switched abruptly and 21.3% (33/155) in patients 
switched by slow tapering.
Over the full treatment period, AEs and serious adverse 
effects (SAEs) contributed to a numerically higher rate of dis-
continuations in the asenapine group (74/467; 15.8%)   versus 
the olanzapine group (48/452; 10.6%). A large proportion 
of the AE/SAE-related discontinuations occurred as a result 
of the patients’ underlying disease. Similar rates of patients 
discontinuing treatment as a result of lack of efficacy were 
seen between the asenapine and olanzapine groups (3.0% 
and 2.6%, respectively). While investigators were requested 
to make a distinction, it is possible that some AEs relating 
to worsening of schizophrenia were reported as a result of 
a lack of efficacy.
Adverse events
In patients receiving at least one antipsychotic medica-
tion during the switch period, 76.9% receiving asenapine 
and 75.2% receiving olanzapine experienced at least one 
treatment-emergent AE over the full 26-week treatment 
period. The majority of these events were reported in the 
initial 28-day switching period (asenapine, 53.1%; olan-
zapine, 49.3%). Over the first 28 days, the most frequently 
reported AEs were somnolence (asenapine, 9.9%; olanzap-
ine, 13.3%), insomnia (asenapine, 9.9%; olanzapine 5.3%), 
and headache (asenapine, 7.5%; olanzapine 5.5%). Over 
the full treatment period, the incidence of somnolence was 
13.5% with asenapine and 15.3% with olanzapine, insomnia 
was 16.9% with asenapine and 11.5% with olanzapine, 
and headache was 13.5% with asenapine and 10% with 
olanzapine.
The majority of AEs in these patients were of mild 
or moderate intensity. A total of 11.6% of patients in the 
asenapine group and 6.0% of patients in the olanzapine group 
experienced at least one SAE. The most common SAEs 
appeared to be disease rather than treatment related.
Of those patients switched to asenapine, 209 were 
switched abruptly (#3 days) and 170 were switched slowly 
($14 days). Of those patients switched to olanzapine, 195 
were switched abruptly and 155 were switched slowly. 
Over the first 28 days, slightly more treatment-emergent 
AEs were reported when switched to asenapine with a slow 
tapered switch (52.4%) than with a rapid switch (48.8%). 
Patients switched to olanzapine reported numerically more 
treatment-emergent AEs when switched abruptly (50.3%) 
than when a slow tapered switch (44.5%) was made. Over the 
full treatment period, numerically more patients experienced 
treatment-emergent AEs with a slow tapered switch than with 
a rapid switch to asenapine (82.9%, 71.8%) or olanzapine 
(80.6%, 70.3%).
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Table 1 Patient demographic and baseline characteristics
Characteristic Asenapine (n = 244) Olanzapine (n = 224) All patients (N = 468)
Study A75010138
Sex, male, n (%) 176 (72.1) 170 (75.9) 346 (73.9)
Race, n (%) 
White 
Black 
Asian 
Other
 
110 (45.1) 
98 (40.2) 
5 (2) 
31 (12.7)
 
95 (42.4) 
95 (42.4) 
2 (0.9) 
32 (14.3)
 
205 (43.8) 
193 (41.2) 
7 (1.5) 
63 (13.5)
Age (years) 
18–64, n (%) 
$65, n (%) 
Mean (SD) 
Median
 
239 (98) 
5 (2) 
43.1 (11.43) 
45
 
217 (96.9) 
7 (3.1) 
42.8 (11.27) 
45
 
456 (97.4) 
12 (2.6) 
42.9 (11.34) 
45
Weight (kg) 
Mean (SD) 
Median (min, max)
 
84 (19.01) 
82.1 (46, 188)
 
85.7 (18.71) 
83.9 (42, 150)
 
84.8 (18.86) 
82.5 (42, 188)
BMI kg/m2 
Mean, n (SD) 
Median (min, max)
 
28.3 (5.72) 
27 (18, 55)
 
28.8 (5.81) 
28.3 (17, 51)
 
28.5 (5.76) 
28 (17, 55)
Total PANSS score (LOCF)
n 
Mean (SD) 
Median (min, max)
228 
75.9 (11.45) 
75.0 (48, 118)
217 
75.4 (11.94) 
74.0 (51, 124)
PANSS positive subscale score (LOCF)
n 
Mean (SD) 
Median (min, max)
234 
18.2 (4.08) 
18.0 (9, 29)
218 
18.2 (4.21) 
18.0 (9, 28)
PANSS Marder negative score (LOCF)
n 
Mean (SD) 
Median (min, max)
234 
26.9 (4.76) 
26.0 (9, 48)
218 
27.0 (4.50) 
26.0 (20, 47)
NSA total score (LOCF)
n 
Mean (SD) 
Median (min, max)
234 
60.1 (10.17) 
60.0 (29, 88)
218 
61.1 (10.79) 
62.0 (23, 87)
Asenapine (n = 241) Olanzapine (n = 240) All patients (N = 481)
Study P255439
Sex, male n (%) 164 (68.0) 164 (68.3) 328 (68.2)
Race, n (%) 
White 
Black 
Asian 
Other
 
216 (89.6) 
16 (6.6) 
9 (0.0) 
9 (3.7)
 
214 (89.2) 
17 (7.1) 
1 (0.4) 
8 (3.3)
 
430 (89.4) 
33 (6.9) 
1 (0.2) 
17 (3.5)
Age (years) 
18–64, n (%) 
$65, n (%) 
Mean (SD) 
Median
 
231 (95.9) 
10 (4.1) 
40.7 (12.73) 
40
 
235 (97.9) 
5 (2.1) 
40.3 (11.65) 
40
 
466 (96.9) 
15 (3.1) 
40.5 (12.19) 
40
Weight (kg) 
Mean (SD) 
Median (min, max)
 
79.3 (15.89) 
79 (44.0, 122.2)
 
80.3 (16.07) 
79 (43.0, 140.0)
 
79.8 (15.97) 
79 (43.0, 140.0)
BMI kg/m2 
Mean, n (SD) 
Median (min, max)
 
26.6 (4.53) 
26 (16.4, 41.0)
 
26.9 (4.83) 
26 (17.5, 44.4)
 
26.7 (4.68) 
26 (16.4, 44.4)
Total PANSS score (LOCF)
n 
Mean (SD) 
Median (min, max)
216 
74.6 (11.3) 
74.0 (51, 108)
217 
73.7 (12.0) 
72.0 (48, 124)
(Continued)
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ziprasidone (numerically higher rate for asenapine). With 
the exception of the switch from aripiprazole to asenapine, 
the majority of the cases of somnolence reported occurred 
in the initial 28 days following switching from an SGA to 
either asenapine or olanzapine.
The respective rates for insomnia when switching from an 
SGA to either asenapine or olanzapine (plotted in Figure 4B) 
show numerically higher rates of insomnia when switching 
from an SGA to asenapine than to olanzapine (the possible 
exception here being quetiapine, where insomnia was more 
frequent in the first 28 days when switching to asenapine, 
but the rates for asenapine and olanzapine were similar over 
the complete treatment period).
The respective rates for reported weight gain were 
numerically lower in patients switched from SGAs to asenap-
ine than to olanzapine over the first 28 days and the entire 
treatment period (Table 3). When switching from an SGA 
to asenapine or olanzapine, weight gain rates were gener-
ally numerically higher in patients switched to olanzapine 
(Figure 4C).
Previous treatment: FgAs
Of patients treated with an FGA (including depot medica-
tions) prior to randomization and during the switch period, 
151 were randomized to asenapine and 138 were randomized 
to olanzapine. Details of the incidence of AEs in patients 
switched from an FGA to asenapine or olanzapine over 
the first 28 days and during the entire treatment period are 
reported in Table 4.
For patients switched from an FGA pretreatment to either 
asenapine or olanzapine, the respective rates of reported AEs 
over the entire study period can be found for somnolence in 
Table 1 (Continued)
Characteristic Asenapine (n = 241) Olanzapine (n = 240) All patients (N = 481)
PANSS positive subscale score (LOCF)
n 
Mean (SD) 
Median (min, max)
216 
11.4 (2. 99) 
11.0 (7, 20)
217 
11.2 (3.05) 
11.0 (7, 20)
PANSS Marder negative score (LOCF)
n 
Mean (SD) 
Median (min, max)
216 
27.0 (3.87) 
27.0 (20, 38)
217 
26.7 (4.07) 
26.0 (20, 44)
NSA total score (LOCF)
n 
Mean (SD) 
Median (min, max)
216 
60.3 (9.03) 
60.0 (38, 81)
217 
60.3 (8.62) 
60.0 (28, 81)
Abbreviations: BMi, body mass index; PANSS, Positive and Negative Syndrome Scale; LOCF, last observation carried forward; NSA, Negative Symptom Assessment;   
SD, standard deviation.
Three deaths were reported during the study. Two deaths 
were in the asenapine treatment group (one suicide, judged 
by the investigator as possibly related to the study drug, and 
one lung cancer death unrelated to the study drug). The one 
death (suicide) occurring in the olanzapine study group was 
considered unrelated to the study drug.
To analyze whether the type or number of previous 
medications influenced the safety and tolerability of 
switching to asenapine or olanzapine, the AE profile of 
patients in each treatment group was summarized by drug 
class (SGAs, FGAs, or depot medications) and by the 
number of antipsychotics that patients were taking dur-
ing the switch period. Over the full time period, similar 
overall rates of AEs were reported when switching to 
either asenapine or olanzapine from SGAs, FGAs, or depot 
medications (Figure 3).
Previous treatment: SgAs
Of patients treated with an SGA before randomization and 
during the switch period, 386 were switched to asenapine 
and 363 to olanzapine. Details of the incidence of AEs in 
patients switched from an SGA to asenapine or olanzap-
ine over the first 28 days and during the entire treatment 
period are reported in Table 3. The AE with the observed 
highest incidence in patients switched to asenapine during 
the first 28 days was insomnia, whereas the AE with the 
highest incidence in patients switched to olanzapine was 
somnolence.
The rates of reported somnolence when switching from an 
SGA to either asenapine or olanzapine are given in Figure 4A. 
Overall, the rates were comparable, with possible differences 
for quetiapine (numerically higher rate for olanzapine) or 
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Figure 4A, for insomnia in Figure 4B and for weight gain in 
Figure 4C. The plots show comparable rates of somnolence 
for the different FGAs used. The majority of reports occurred 
in the first 28 days.
Previous treatment: depot formulations only
Of the patients who received a depot medication prior to 
randomization (last injection of a depot was given no later 
than one dosing cycle prior to randomization), 60 switched to 
asenapine and 53 switched to olanzapine. Details of the inci-
dence of AEs in patients switched from a depot medication 
to asenapine or olanzapine over the first 28 days and during 
the entire treatment period are reported in Table 5.
Few patients switched from a depot medication to 
asenapine reported weight gain throughout the duration of the 
studies compared with nearly half of the patients switched to 
olanzapine. Those switched from flupentixol reported notably 
increased rates of weight gain as detailed earlier.
Table 2 Summary of pretreatment antipsychotic drug use during 
cross-titration period
Asenapine  
(n = 485)
Olanzapine 
(n = 464)
Antipsychotics, n (%)
Total 467 (96.3) 452 (97.4)
1 329 (67.8) 335 (72.2)
2 107 (22.1) 93 (20.0)
3 or more 31 (6.4) 24 (5.2)
Antipsychotic class, n (%)
FgA 151 (31.1) 138 (29.7)
SgA 386 (79.6) 363 (78.2)
Depot 60 (12.4) 53 (11.4)
Antipsychotic, n (%)
SGA
Olanzapine 132 (27.2) 109 (23.5)
Risperidone 163 (33.6) 151 (32.5)
Quetiapine 63 (13.0) 57 (12.3)
Ziprasidone 16 (3.3) 22 (4.7)
Aripiprazole 28 (5.8) 41 (8.8)
Amisulpride 17 (3.5) 14 (3.0)
Clozapine 14 (2.9) 8 (1.7)
Clotiapine 4 (0.8) 0 (0.0)
Paliperidone 2 (0.4) 3 (0.6)
Ziprasidone mesilate 2 (0.4) 2 (0.4)
Zotepine 0 (0.0) 2 (0.4)
Melperone hydrochloride 0 (0.0) 1 (0.2)
Sertindole 0 (0.0) 1 (0.2)
FGA
Haloperidol 53 (10.9) 47 (10.1)
Chlorpromazine 12 (2.5) 23 (5.0)
Levomepromazine 14 (2.9) 9 (1.9)
Fluphenazine 
Trifluoperazine 
Promethazine 
Sulpiride 
Thioridazine 
Chlorprothixene 
Loxapine 
Cyamemazine 
Tiapride 
Pipotiazine 
Benperidol 
Pimozide 
Thioproperazine 
Zuclopenthixol 
Depot 
Fluphenazine decanoate 
Flupentixol 
Zuclopenthixol 
Flupentixol decanoate 
Haloperidol decanoate 
Perphenazine 
Perphenazine enantate 
Zuclopenthixol decanoate 
Perphenazine decanoate
11 (2.3)
9 (1.9)
10 (2.1) 
8 (1.6) 
5 (1.0) 
4 (0.8) 
4 (0.8) 
4 (0.8) 
2 (0.4) 
1 (0.2) 
1 (0.2) 
1 (0.2) 
1 (0.2) 
1 (0.2) 
 
11 (2.3) 
19 (3.9) 
15 (3.1) 
0 (0.0) 
8 (1.6) 
8 (1.6) 
0 (0.0) 
1 (0.2) 
1 (0.2)
9 (1.9)
11 (2.4)
7 (1.5) 
5 (1.1) 
3 (0.6) 
11 (2.4) 
2 (0.4) 
2 (0.4) 
0 (0.0) 
1 (0.2) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
1 (0.2) 
 
13 (2.8) 
21 (4.5) 
6 (1.3) 
2 (0.4) 
8 (1.7) 
3 (0.6) 
2 (0.4) 
1 (0.2) 
0 (0.0)
Abbreviations:  FGA,  first-generation  antipsychotic;  SGA,  second-generation 
antipsychotic.
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Effect of the number of antipsychotics  
in pretreatment
The incidences of reported AEs grouped by the number of 
antipsychotics taken as pretreatments by patients during the 
switch period are listed in Table 6. Over the full treatment 
period, the number of antipsychotics during the switch 
appeared to have no major influence on somnolence rate 
when switching to asenapine, while the respective numbers 
varied for olanzapine.
Patients switched to olanzapine from olanzapine
A subpopulation of patients randomized to switch to olan-
zapine was taking olanzapine prior to randomization and 
during the switch period. This previous treatment with the 
comparator drug was not exclusionary unless insufficient 
clinical response, despite adequate dosing, was documented 
at screening. These patients did not effectively undergo 
switch therapy and their inclusion in the AE analysis may 
have decreased the sensitivity of AE detection in olanzap-
ine switch patients. To eliminate this possible bias, AE 
data have also been analyzed to exclude all patients who 
were taking olanzapine as pretrial medication before the 
switch phase (132 patients were excluded from the group 
randomized to asenapine and 109 from the group random-
ized to olanzapine). After these subjects were excluded 
from analysis, 77.3% of the asenapine group and 73.4% 
of the olanzapine group reported at least one AE over the 
full treatment period. This was comparable to the 76.9% 
and 75.2% of patients reporting at least one AE from the 
full treatment groups.
When data from patients using olanzapine prior to the 
switch period were excluded from the analysis, the overall 
discontinuation rates increased in both treatment groups 
(45.5% of patients in the asenapine group [n = 132] and 
24.8% in the olanzapine group [n = 109] discontinued 
  treatment). In this subpopulation of patients, lack of efficacy 
as a cause of discontinuation in those switched to asenapine 
was numerically greater (9.8%) than in the full patient popu-
lation (3.0%) and numerically decreased in those patients 
switched to olanzapine (1.8%). AEs or SAEs as a cause 
of discontinuation increased in both the asenapine group 
(20.5%) and the olanzapine group (13.8%).
Discussion
The results from these post hoc analyses can be a useful 
source of information for clinicians faced with the clinical 
need to switch medication in patients partially stabilized with 
an antipsychotic and who consider switching to the relatively 
new treatment option asenapine or the well-established alter-
native olanzapine. Though switching treatments was not the 
primary objective of the studies, the analyses are informative 
in this regard because they were performed in a large pooled 
dataset of patients previously treated with various antipsy-
chotic agents who had achieved partial symptom control and 
stabilization for at least 6 months (both historically and pro-
spectively documented) before either asenapine or olanzapine 
Table 3 Adverse events (AEs) in patients treated with second-generation antipsychotics during the switch period
Preferred term, n (%) Switch period (first 28 days) Full treatment period (26 weeks)
Asenapine (n = 386) Olanzapine (n = 363) Asenapine (n = 386) Olanzapine (n = 363)
At least one AE 209 (54.1) 173 (47.7) 299 (77.5) 272 (74.9)
insomnia 43 (11.1) 22 (6.1) 73 (18.9) 47 (12.9)
Somnolence 38 (9.8) 46 (12.7) 53 (13.7) 52 (14.3)
Headache 33 (8.5) 23 (6.3) 56 (14.5) 37 (10.2)
Nausea 18 (4.7) 9 (2.5) 27 (7.0) 16 (4.4)
Agitation 11 (2.8) 5 (1.4) 19 (4.9) 7 (1.9)
Anxiety 17 (4.4) 11 (3.0) 42 (10.9) 31 (8.5)
Dizziness 17 (4.4) 12 (3.3) 21 (5.4) 20 (5.5)
Akathisia 14 (3.6) 7 (1.9) 24 (6.2) 15 (4.1)
Sedation 14 (3.6) 15 (4.1) 20 (5.2) 21 (5.8)
Hypoesthesia oral 12 (3.1) 0 (0.0) 12 (3.1) 0 (0)
Dysgeusia 10 (2.6) 1 (0.3) 10 (2.6) 2 (0.6)
Fatigue 9 (2.3) 12 (3.3) 18 (4.7) 20 (5.5)
Nasopharyngitis 9 (2.3) 5 (1.4) 16 (4.1) 16 (4.4)
Vomiting 8 (2.1) 4 (1.1) 14 (3.6) 5 (1.4)
Weight increase 7 (1.8) 8 (2.2) 28 (7.3) 65 (17.9)
Weight decrease 2 (0.5) 0 (0) 17 (4.4) 3 (0.8)
increased appetite 6 (1.6) 10 (2.8) 8 (2.1) 13 (3.6)
Dry mouth 3 (0.8) 14 (3.9) 9 (2.3) 18 (5.0)
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•	 When clinicians applied various tapering regimens of 
pretreatment antipsychotics, including abrupt discontinu-
ation up to 3 days after the addition of either asenapine 
or olanzapine at adequate doses, the switch appeared to 
be generally safe and well tolerated. Discontinuation 
rates were numerically higher for asenapine than with 
olanzapine, however, the discontinuation rates were 
within the range seen in other studies conducted with 
compounds deemed to be well tolerated in comparable 
populations.
•	 The three most frequently reported AEs within 28 days 
for asenapine were insomnia, somnolence, and headache, 
and for olanzapine the three most frequently reported 
AEs were somnolence, headache, and insomnia (all AEs 
occurring in approximately #10% patients).
•	 For asenapine, the overall rate of reported AEs was simi-
lar irrespective of whether patients were pretreated with 
an SGA, an FGA, or a depot formulation. For olanzapine, 
a larger variability depending on the pretreatment was 
observed.
•	 Upon the switch, minimal variation was observed in 
mean changes of positive symptoms. This indicates 
that for a majority of patients the previously achieved 
symptom control over positive symptoms continued 
after the switch. While individual reactions may have 
differed from patient to patient, this result is encourag-
ing, as there may be a good chance to maintain symp-
tom control after a switch to the used compounds. The 
changes in negative symptoms over time, the primary 
objectives of these trials, have been reported and dis-
cussed elsewhere.10
When clinicians select a candidate drug to switch to, 
the pharmacological profile of an antipsychotic drug, its 
propensity to induce weight gain and metabolic changes, 
as well as its overall side-effect profile will be taken into 
account, particularly if longer-term treatment is necessary. 
Treatment with olanzapine is reported to be associated with 
a high risk of substantial weight gain.11–13 In this study, we 
also found that olanzapine induced weight gain in a sizable 
subset of patients.
In 2011, the US Food and Drug Administration issued 
a warning that serious allergic reactions had been reported 
with the use of asenapine.14 These included 52 cases of 
Type I hypersensitivity reactions (allergic reactions). In the 
pooled data from the two studies reported here, one case of 
hypersensitivity was observed. The subject was switched 
from olanzapine abruptly to asenapine and reported mild 
nasal allergies on day 126 of treatment.
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Figure 4 Rate of (A) somnolence, (B) insomnia, and (C) incidence of weight gain by 
antipsychotic taken during the switch period.
Abbreviations:  FgA,  first-generation  antipsychotic  (most  frequently  used); 
SgA, second-generation antipsychotic.
were added in a double-blind fashion and variable regimens 
were used according to the treating clinician’s judgment to 
taper off the previous treatment.
The overall results from our analyses suggest the 
  following clinical conclusions:
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Table 4 Adverse events (AEs) in patients treated with first-generation antipsychotics (including depot) during the switch period
Preferred term, n (%) Switch period (first 28 days) Full treatment period (26 weeks)
Asenapine (n = 151) Olanzapine (n = 138) Asenapine (n = 151) Olanzapine (n = 138)
At least one AE 69 (45.7) 80 (58.0) 114 (75.5) 110 (79.7)
Somnolence 13 (8.6) 21 (15.2) 20 (13.2) 23 (16.7)
Nausea 7 (4.6) 3 (2.2) 8 (5.3) 7 (5.1)
insomnia 7 (4.6) 5 (3.6) 17 (11.3) 13 (9.4)
Dizziness 5 (3.3) 5 (3.6) 8 (5.3) 7 (5.1)
Headache 5 (3.3) 5 (3.6) 12 (7.9) 12 (8.7)
Dyspepsia 5 (3.3) 2 (1.4) 6 (4.0) 3 (2.2)
Anxiety 5 (3.3) 1 (0.7) 12 (7.9) 11 (8.0)
Agitation 4 (2.6) 3 (2.2) 9 (6.0) 4 (2.9)
Dysgeusia 4 (2.6) 0 (0.0) 5 (3.3) 0 (0.0)
Sedation 4 (2.6) 4 (2.9) 5 (3.3) 5 (3.6)
Weight increase 2 (1.3) 17 (12.3) 9 (6.0) 43 (31.2)
Weight decrease 0 (0.0) 1 (0.7) 4 (2.6) 2 (1.4)
Back pain 1 (0.7) 4 (2.9) 1 (0.7) 7 (5.1)
increased appetite 1 (0.7) 6 (4.3) 2 (1.3) 7 (5.1)
Paresthesia 1 (0.7) 3 (2.2) 1 (0.7) 3 (2.2)
Fatigue 0 (0.0) 3 (2.2) 3 (2.0) 3 (2.2)
Myalgia 0 (0.0) 3 (2.2) 0 (0.0) 3 (2.2)
Table 5 Adverse events (AEs) in patients treated with depot medications during the switch period
Preferred term, n (%) Switch period (first 28 days) Full treatment period (26 weeks)
Asenapine (n = 60) Olanzapine (n = 53) Asenapine (n = 60) Olanzapine (n = 53)
At least one AE 30 (50.0) 38 (71.7) 51 (85.0) 46 (86.8)
Somnolence 7 (11.7) 14 (26.4) 9 (15.0) 14 (26.4)
Nausea 1 (1.7) 1 (1.9) 1 (1.7) 3 (5.7)
insomnia 6 (10.0) 2 (3.8) 9 (15.0) 3 (5.7)
Dizziness 1 (1.7) 2 (3.8) 2 (3.3) 3 (5.7)
Headache 2 (3.3) 3 (5.7) 7 (11.7) 7 (13.2)
Dyspepsia 2 (3.3) 1 (1.9) 3 (5.0) 2 (3.8)
Anxiety 1 (1.7) 0 (0.0) 5 (8.3) 3 (5.7)
Agitation 4 (6.7) 2 (3.8) 6 (10.0) 2 (3.8)
Dysgeusia 1 (1.7) 0 (0.0) 1 (1.7) 0 (0.0)
Sedation 0 (0.0) 1 (1.9) 0 (0.0) 2 (3.8)
Weight increase 1 (1.7) 13 (24.5) 5 (8.3) 25 (47.2)
Weight decrease 0 (0.0) 0 (0.0) 3 (5.0) 0 (0.0)
Back pain 1 (1.7) 2 (3.8) 1 (1.7) 3 (5.7)
increased appetite 1 (1.7) 4 (7.5) 1 (1.7) 0 (0.0)
Paresthesia 0 (0.0) 1 (1.9) 0 (0.0) 1 (1.9)
Fatigue 0 (0.0) 1 (1.9) 2 (3.3) 1 (1.9)
Table 6 Effect of number of pre-switch antipsychotics used during switch on incidence of adverse events over the full treatment period 
(26 weeks)
Asenapine (5–10 mg twice daily) Olanzapine (5–20 mg once daily)
Patients (n) 329 107 23 335 93 19
Pretreatment antipsychotics (n) 1 2 3 1 2 3
Total (%) 76.3 79.4 73.9 72.2 83.9 84.2
Somnolence (%) 14.0 14.0 8.7 14.6 21.5 0
Sedation (%) 5.5 2.8 4.3 6.9 3.2 0
insomnia (%) 14.9 24.3 8.7 9.9 15.1 15.8
Weight increase (%) 7.6 5.6 0 20.9 26.9 5.3
Weight decrease (%) 3.6 5.6 8.7 0.6 1.1 5.3
Headache (%) 14.9 11.2 4.3 11.0 8.6 0
Nausea (%) 7.0 8.4 0 3.0 7.5 0
Anxiety (%) 8.5 15.0 8.7 7.2 7.5 15.8
Agitation (%) 4.3 6.5 4.3 0 6.5 0
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Limitations
The presented analyses are retrospective rather than prospec-
tive and some subanalyses are based on a limited number of 
patients. The presented data are exploratory in nature; they 
had not been designed and powered for the different analyses 
performed in the pooled dataset. The absence of a control 
group of patients who did not switch therapy may also limit 
the generalizability of the results. Also, the fact that the 
data are derived from a set of patients with schizophrenia 
partially stabilized on positive symptoms may not allow the 
conclusions to be generalized to patients who are acutely ill, 
treatment resistant, or who have been diagnosed with bipolar 
disorder. Given the mentioned limitations, the clinical conclu-
sions should be regarded as tentative. Further, it should be 
kept in mind that a large variability of patient reactions can be 
expected in the clinical setting and patients may react differ-
ently than expected based on the presented data. This may be 
relevant for the comparability of the safety of the switching 
methods of abrupt discontinuation versus slow taper. The 
physician must weigh the risks associated with both methods: 
an abrupt discontinuation’s association with a higher risk of 
recurrence versus a slow taper’s association with drug–drug 
interaction on a case-by-case basis.   Nevertheless, the study 
does provide relevant data for clinicians and patients, if 
switching is considered clinically necessary.
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